

# VALUE & OUTCOMES SPOTLIGHT

MAY/JUNE 2017 VOL. 3, NO. 3

## VALUE & OUTCOMES SPOTLIGHT EDITORS & EDITORIAL BOARD

**EDITOR-IN-CHIEF** – David Thompson, PhD,  
Real World Evidence & Insights, Inventiv Health,  
Boston, MA, USA  
david.thompson@inventivehealth.com

**CO-EDITORS** – Murtuza Bharmal, PhD,  
Merck KGaA, Germany; Benjamin Craig, PhD,  
University of South Florida, USA

**EDITORIAL BOARD** – Syed Mohamed Aljunid,  
PhD, United Nations University-International  
Institute For Global Health, Malaysia; Soraya  
Azmi, MBBS, MPH, Azmi Burhani Consulting,  
Malaysia; Amit Chhabra, MD, MPH, Pfizer, Inc.,  
USA; Benjamin Craig, PhD, H. Lee Moffitt Cancer  
Center & Research Institute, USA; Yvonne Lee,  
MPH, Pfizer, Malaysia; Martin Marciniak, PhD,  
GlaxoSmithKline, USA; Axel C. Mühlbacher,  
PhD, MBA, HS Neubrandenburg, Germany;  
George Papadopoulos, BSc(Hons), Emerald  
Corporate Group Pty., Ltd., Australia; Stephen  
W. Schondelmeyer, PhD, University of Minnesota,  
USA; Gabriela Tannus, MSc, Axia.Bio, Brazil;  
Mondher Toumi, MD, PhD, MSc, University  
Aix-Marseille/Creativ-Ceutical, France; Gergana  
Zlateva, PhD, Pfizer, Inc., USA

**MANAGEMENT ADVISORY BOARD** – Nancy Devlin,  
PhD, OHE, UK; Josephine Mauskopf, PhD, RTI  
Health Solutions, USA; Gordon Liu, PhD, Peking  
University National School of Development, China

## VALUE & OUTCOMES SPOTLIGHT PUBLISHING, SUBSCRIPTION, AND ADVERTISING OFFICE:

*Value & Outcomes Spotlight*  
Print: ISSN 2375-866X  
Online: ISSN 2375-8678  
USPS: 019121

Published bi-monthly by:  
ISPOR

505 Lawrence Square Blvd. South  
Lawrenceville, NJ 08648 USA  
Tel: 609-586-4981; Toll Free: 1-800-992-0643  
Fax: 609-586-4982; Website: [www.ispor.org](http://www.ispor.org)

Periodicals Postage paid at Annapolis, MD 21401  
and at additional mailing offices.

POSTMASTER: Send address changes to:

*Value & Outcomes Spotlight*  
505 Lawrence Square Blvd., South  
Lawrenceville, NJ 08648 USA

**Managing Editor:** Stephen L. Priori  
email: [spriori@ispor.org](mailto:spriori@ispor.org)

**Advertising Coordinator:** Lyn Beamesderfer  
email: [lbeamesderfer@ispor.org](mailto:lbeamesderfer@ispor.org)

Direct photocopy permission and reprint requests  
to Managing Editor.

© 2017 International Society for Pharmacoeconomics and  
Outcomes Research (ISPOR). All rights reserved under  
International and Pan-American copyright conventions.

While *Value & Outcomes Spotlight* is designed to provide  
accurate information regarding the subject matters covered, the  
views, opinions, and recommendations expressed, are those of  
the contributors and not of the International Society for  
Pharmacoeconomics and Outcomes Research (ISPOR).

## LETTER FROM THE EDITOR



This issue of *Value & Outcomes Spotlight* comes on the heels of ISPOR's 22nd Annual International Meeting in Boston. Approximately 4,200 attendees enjoyed a wide ranging program of short courses, plenaries, issue panels, workshops, oral presentations, and posters. Though not a native-Bostonian, I have resided in the greater-Boston area for more than 30 years and consider New England my home—which made this year's ISPOR meeting all the more special.

The meeting theme was “*Evidence and Value in a Time of Social and Policy Change*.” If that sounds like a nod to the current global political environment, then the first plenary session did not disappoint. With the provocative title, “*Where Is US Health Policy Going?*” the panel discussion included four health economists who have counseled US policymakers across the political spectrum, with former ISPOR President Peter Neumann moderating. Despite the intended balance, the discussion soon focused on the perils of Obamacare repeal, not only from the standpoint of loss in health insurance for more than 20 million Americans but also from the perspective of what a political hot potato the issue has become for Republicans and Democrats alike.

We carry that policy theme into this issue, though our focus is not on the provision of health insurance coverage, but rather the evolving relationship between regulatory policy and real-world research. In our last issue we talked about the “topsy-turvy” nature of this relationship at present, with regulatory authorities in the US and Europe now in a position to impact the creation of real-world evidence after more than a century of real-world evidence impacting the creation of regulatory policy.

The first article addresses aspects of the US 21st Century Cures Act that relate to the dissemination by manufacturers of health-care economic information (HCEI), which has spurred the Food & Drug Administration to provide—finally, according to the author—guidance to manufacturers on best practices for communication of non-misleading HCEI to health care system stakeholders. The second article considers the “adaptive pathways” schema for accelerated regulatory approval put forth by the European Medicines Agency (EMA), which permits early approval in a limited in size, well-defined population accompanied by a milestone-based plan for continued evidence generation—this brings challenges in demonstrating product value, highlighted by the author. The third article draws attention to the particularities of medical devices, providing insights into the challenges of assessing product value from industry, payer, and regulatory perspectives.

Finally, we come back to the Boston meeting with a variety of features, including a report from the ISPOR student chapter leadership on their activities at the meeting; a summary of social media activity and other connections during the conference; a listing of award winners; and a photo gallery of all the happy attendees.

Best regards,

David Thompson, PhD  
Editor-in-Chief, *Value & Outcomes Spotlight*

Tell us what you think of *Value & Outcomes Spotlight*! Send feedback to [vos@ispor.org](mailto:vos@ispor.org) or use the comments form at <http://www.ispor.org/ValueOutcomesSpotlight/CommentForm>